Elicio Therapeutics, Inc. develops cancer immunotherapies that utilize a lymph node-targeted platform to enhance the immune response against solid tumors. The company focuses on creating next-generation vaccines, immunomodulators, and adjuvants through its AMP platform, with a particular emphasis on treating challenging cancers such as pancreatic ductal adenocarcinoma (PDAC). Elicio's approach aims to activate and amplify cancer-fighting T cells to improve patient outcomes in the fight against aggressive tumors.
